Loading
A phase 2 trial of anlotinib, benmelstobart and capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy is a phase 2, randomised interventional study registered as NCT06992336 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 411 participants, started 2025-04-10 and due to reach its primary completion in 2031-04-10. Interventions recorded: Anlotinib ,; Benmelstobart; Capecitabine. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "* TNBC patients". Sites: China. No results are recorded here; the registry entry is the source.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.